Tenofovir (all routes except local)

Child/Infant weight abnormalities (> 1 year)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5160
R13454		 Pintye, 2015 9-months z-scores for weight-for-age (WAZ) < −2 SD during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: Yes Control group: zidovudine/lamivudine/nevirapine Exposed group: TDF/lamivudine-based Indication: HIV 1.60 [0.56;4.56] 7/38   10/84 17 38
ref
S5127
R13318		 Ransom, 2013 Low weight at 6 months of age (age and sex adjusted z- score <5th percentile) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: Yes Control group: non-TDF (mix or unspecified regimens) Exposed group: TDF (mix or unspecified regimens) Indication: HIV 1.40 [0.81;2.36] 24/457   37/1,039 61 457
ref
S5124
R13306		 Siberry, 2012 Low weight at one year (gestation-or age-adjusted z-score< −1.5) during pregnancy (anytime or not specified) cohort exposed to other treatment, sick Adjustment: Yes Control group: non-TDF (mix or unspecified regimens) Exposed group: TDF (mix or unspecified regimens) Indication: HIV 1.25 [0.73;2.17] 25/217   35/368 60 217
ref
Total 3 studies 1.35 [0.95;1.94] 138 712
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Pintye, 2015Pintye, 2015 1.60[0.56; 4.56]173812%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Ransom, 2013Ransom, 2013 1.40[0.81; 2.36]6145745%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Siberry, 2012Siberry, 2012 1.25[0.73; 2.17]6021743%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 1.35[0.95; 1.94]1387120.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.35[0.95; 1.94]1387120%NAPintye, 2015 Ransom, 2013 Siberry, 2012 3 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 1.35[0.95; 1.94]1387120%NAPintye, 2015 Ransom, 2013 Siberry, 2012 3 Tags Adjustment   - Yes  - Yes 1.35[0.95; 1.94]1387120%NAPintye, 2015 Ransom, 2013 Siberry, 2012 3 Control group   - non-TDF (mix or unspecified regimens)  - non-TDF (mix or unspecified regimens) 1.32[0.90; 1.94]1216740%NARansom, 2013 Siberry, 2012 2   - zidovudine/lamivudine/nevirapine  - zidovudine/lamivudine/nevirapine 1.60[0.56; 4.57]1738 -NAPintye, 2015 1 Exposed group   - TDF (mix or unspecified regimens)  - TDF (mix or unspecified regimens) 1.32[0.90; 1.94]1216740%NARansom, 2013 Siberry, 2012 2   - TDF/lamivudine-based  - TDF/lamivudine-based 1.60[0.56; 4.57]1738 -NAPintye, 2015 1 Indication   - HIV  - HIV 1.35[0.95; 1.94]1387120%NAPintye, 2015 Ransom, 2013 Siberry, 2012 3 All studiesAll studies 1.35[0.95; 1.94]1387120%NAPintye, 2015 Ransom, 2013 Siberry, 2012 30.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.35[0.95; 1.94]1387120%NAPintye, 2015 Ransom, 2013 Siberry, 2012 30.510.01.0